Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway

Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle™ PlatformSAN DIEGO, Calif., ...
Le Lézard

FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements

FORE Biotherapeutics, a registration stage company dedicated to developing targeted therapies to treat patients with cancer, today announced the closing of an upsized Series D-2 extension financing of ...
AHA/ASA Journals

Neighborhood Social Determinants of Health and Referral to Cardiac Rehabilitation: An Analysis of the Get With The Guidelines–Coronary Artery Disease Registry

BACKGROUND: Despite strong guideline recommendations for cardiac rehabilitation (CR) following an acute myocardial infarction ...